Over the past year, high medicine prices have made the headlines. In the UK, two cancer treatments were dropped because they were deemed too expensive. A US Senate subcommittee criticized pharmaceutical company Gilead for charging $84,000 (£57,000) for a full course of its new hepatitis C treatments and found that fostering broad, affordable access for other drugs was not a major concern for the firm.
Continue reading....
No comments:
Post a Comment